Dr. Kundranda on the Sequencing of Second-Line Therapies in HCC
Madappa Kundranda, MD, PhD, discusses the sequencing of second-line therapies in hepatocellular carcinoma.
Dr. Kundranda on the Need for Novel Treatments in Pancreatic Ductal Adenocarcinoma
Madappa Kundranda, MD, PhD, discusses the need to develop novel treatments in pancreatic ductal adenocarcinoma.
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512